Literature DB >> 11030482

The implications of genetics studies of major mood disorders for clinical practice.

A Duffy1, P Grof, C Robertson, M Alda.   

Abstract

BACKGROUND: This article is a selective review and synthesis of relevant research findings from genetic studies of major mood disorders and the application of these to clinical practice.
METHOD: The article discusses the application of genetic research findings in major mood disorders, including epidemiologic and family study risk estimates, risk modifiers, and the concepts of etiologic and phenotypic heterogeneity, to 3 clinical domains: risk counseling, diagnosis, and treatment prediction.
RESULTS: Epidemiologic and family studies have provided general risk estimates useful in counseling mood-disordered patients and their relatives. A complete and accurate family pedigree provides more individualized risk estimates for specific cases and is useful in identifying the phenotypic spectrum of the disorder being transmitted in the family. Both proband course parameters and familial loading for psychiatric illnesses may be relevant for the prediction of treatment response. However, the hypothesis of inherited pharmacologic selectivity remains to be proven.
CONCLUSION: Genetic studies of mood disorders have not yet provided conclusive evidence of specific susceptibility genes or their pattern of inheritance. However, they have generated information that is useful to clinical practice.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11030482     DOI: 10.4088/jcp.v61n0906

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  21 in total

1.  Association between HTR2A T102C polymorphism and major depressive disorder: a meta-analysis in the Chinese population.

Authors:  Chun-Xia Lin; Zhe Hu; Ze-Ming Yan; Wen Li; Yu-Sen Chen; Jiang-Hao Zhao; Liang-Qing Zhang; Bin Zhao; Wang-Tao Zhong; Du Feng
Journal:  Int J Clin Exp Med       Date:  2015-11-15

Review 2.  Toward a comprehensive clinical staging model for bipolar disorder: integrating the evidence.

Authors:  Anne Duffy
Journal:  Can J Psychiatry       Date:  2014-12       Impact factor: 4.356

Review 3.  Emerging risk factors for postpartum depression: serotonin transporter genotype and omega-3 fatty acid status.

Authors:  Gabriel D Shapiro; William D Fraser; Jean R Séguin
Journal:  Can J Psychiatry       Date:  2012-11       Impact factor: 4.356

Review 4.  Association of HTR2A T102C and A-1438G polymorphisms with susceptibility to major depressive disorder: a meta-analysis.

Authors:  Xue Zhao; Liang Sun; Ye-Huan Sun; Cizao Ren; Jian Chen; Zhen-Qiang Wu; Yu-Hong Jiang; Xiao-Ling Lv
Journal:  Neurol Sci       Date:  2014-10-01       Impact factor: 3.307

5.  Brain-derived neurotrophic factor (BDNF) polymorphisms G196A and C270T are not associated with response to electroconvulsive therapy in major depressive disorder.

Authors:  Kaija Huuhka; Sami Anttila; Martti Huuhka; Esa Leinonen; Riikka Rontu; Kari Mattila; Terho Lehtimäki
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-02       Impact factor: 5.270

Review 6.  Subthreshold bipolarity: diagnostic issues and challenges.

Authors:  Robin Nusslock; Ellen Frank
Journal:  Bipolar Disord       Date:  2011 Nov-Dec       Impact factor: 6.744

7.  Family risk and related education and counseling needs: perceptions of adults with bipolar disorder and siblings of adults with bipolar disorder.

Authors:  H L Peay; G W Hooker; L Kassem; B B Biesecker
Journal:  Am J Med Genet A       Date:  2009-03       Impact factor: 2.802

8.  The early course of bipolar disorder in youth at familial risk.

Authors:  Anne Duffy
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2009-08

Review 9.  Ethical issues in psychiatric genetics research: points to consider.

Authors:  Barbara Bowles Biesecker; Holly Landrum Peay
Journal:  Psychopharmacology (Berl)       Date:  2003-09-10       Impact factor: 4.530

Review 10.  Bipolar II disorder : epidemiology, diagnosis and management.

Authors:  Franco Benazzi
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.